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Phenotypic manifestations for young children with 
fragile X syndrome (FXS) include:  anxiety, sensory 
processing challenges, global language and 
communication deficits and intellectual and 
developmental disabilities. Many of these symptoms 
can be treated with medications, including selective 
serotonin reuptake inhibitors (SSRIs).   However to 
date a clinical trial has not been conducted for children 
under five years old.  
 
This study investigated the following question: 
Are there group differences on developmental 
outcome measures for those children treated with 
sertraline compared to placebo?  
 
INTRODUCTION and PURPOSE 
PARTICIPANTS and DESIGN 
RESULTS RESULTS CONCLUSIONS 
• Significant improvements for the sertraline treatment 
group found in:   
General functioning 
Overall behavior, specifically hyperactivity, 
impulsivity and attention 
Cognition 
 Social Participation:  family social events 
and community activities 
• Improvements in behavior, particularly hyperactivity, 
impulsivity and attention may influence improved 
social participation in family activities and the 
community and thus overall family quality of life. 
• Unique interdisciplinary and collaborative approach 
to a clinical trial.   
Expertise from scientists and clinicians from 
the fields of medicine, occupational therapy, 
psychology, education, speech language 
pathology 
A collaborative and interdisciplinary 
approach to research is a mirror to what best 
practices are for intervention for children 
with FXS.  Our research provides a model 
for future clinical trials. 
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Type of 
Assessment 
 
Outcome 
Measures 
Outcome 
Domains 
 
Placebo vs. 
Treatment 
Groups 
SSRI 
Sertraline 
Global 
Improvement CGI-I Clinician Tool 
Behavior VAS 
Parent 
Response 
Cognition Mullen ELC Direct Assessment 
Language 
PLS-5 
Mullen RL/EL 
Direct 
Assessment 
Sensory 
Processing 
SPM-P Parent 
Response 
ASD 
Symptoms ADOS-2 
Direct 
Assessment 
Very Much 
Worse 
Much Worse 
Minimally 
Worse 
No Change 
Minimally 
Improved 
Much 
Improved 
Very Much 
Improved 
Placebo N=17 0 0 0 18 47 35 0 
Sertraline N= 13 0 0 0 23 23 8 46 
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Global Improvement 
Clinical Global Impressions - Improvement 
(CGI-I), Percentage of Sample by Group 
Placebo  
35% 
 
Sertraline 
54% 
Total (90 behaviors) 
Anxiety Sensory      (P-
17, S -13) 
Behavioral Excesses 
(P-13, S-6) 
Hyperactivity 
Impulsivity Attention 
(P - 8, S -10) 
Language Speech 
Communication        
(P-11, S-10) 
Placebo Baseline 2.5 3.3 2.3 2.6 1.4 
Placebo 6 months 4.3 4.6 4.8 2.5 4.8 
Sertraline Baseline 2.8 3.2 2.6 2.5 2.8 
Sertraline 6 months 5.8 5.9 6.2 5.2 6 
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Behavior 
Visual Analogue Scale (VAS)  
Total and Behavioral Categories 
VR Raw FM Raw RL Raw EL Raw ELC SS 
Placebo Baseline 29.2 24.4 23.5 18 54.3 
Placebo Post 31.7 25.4 27.4 22.1 52.8 
Sertraline Baseline 28.2 24.8 25.2 23.1 61.9 
Sertraline Post 32.9 27.4 29.1 26.3 64.5 
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Cognition 
Mullen Mean Raw Scores and ELC Standard Score 
Early Learning Composite (ELC), F(1,28)=3.79, p=.062, eta2 = .119 
X2 (3, N=30) = 11.52, p = .009. 
Total Behaviors, F(1,88) = 4.36, p=.040, eta2 = .047 
HIA - F(1,16) = 6.33, p=.023, eta2 = .284 
SOC Raw VIS Raw HEA Raw TOU Raw BOD Raw BAL Raw PLA Raw 
Placebo Baseline 20.8 25.3 16.9 29.7 18.5 19.6 18.9 
Placebo Post 21.9 24.7 15.8 26.3 17.6 18.1 18.8 
Sertraline Baseline  18.3 20.3 16.6 26.1 16.2 17.7 19.8 
Sertraline Post 16.1 19.4 15.3 23.9 16.9 15.6 18.1 
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Sensory Processing 
Sensory Processing Measure (SPM) Mean Raw Scores 
Social Participation Raw Score, F(1,24) = 6.65, p = .016, eta2 = .22  
Social Participation Item Analysis:  Family outings, gatherings, activities 
with friends and family errands 
No significant differences between groups found on side effects:  
Severity:   X2 (2, N=171) = .856, p = .652 
Adverse event type:  X2 (7, N=171) = 8.26, p = .310 
(1) Pediatrics, MIND Institute, UC Davis, Sacramento, CA, (2) School of Education, UC Davis, Davis, CA  
